Examining how gut bacteria and vitamin D affect allergic diseases in infants

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational birth cohort study aims to evaluate the influence of the human microbiome and vitamin D on the development of allergic diseases in infants under one year of age. It focuses on understanding how genetic and environmental factors, particularly early exposure to allergens and microbes, contribute to conditions like atopic dermatitis, allergic rhinitis, and asthma. The study will assess the relationship between vitamin D levels, vitamin D binding protein, and gut microbiota colonization in newborns. By analyzing these factors, the researchers hope to uncover the mechanisms behind the increasing prevalence of allergic diseases in young children.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All term newborn babies who are born in China Medical University Hospital. The term baby defines the maternal gestational age between 37 0/7 weeks to 41 6/7 weeks.

Exclusion Criteria:

* The exclusion criteria are prematurity newborn, congenital anomalies and cardiopulmonary failure need for resuscitation immediately after birth.

Where it's running

• China Medical University Hospital
  Taichung, Taiwan Recruiting

Study contacts

• Study coordinator: Jiu-Yao Wang, MD
• Email: aim.cmuh@gmail.com
• Phone: 886422052121

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FaceSay: a computer program to help kids recognize facial expressions and improve social interactions

  A computer-based FaceSay program is tested to see if it helps survivors of pediatric brain tumors who have social difficulties see facial expressions better and relate more comfortably with peers.

  Recruiting Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT07923370

• Access to Innovative Cancer Treatments for Children and Young People in Belgium

  This observational study collects safety and effectiveness data on off‑label and compassionate cancer medicines used in kids and young adults up to age 25 in Belgium.

  Recruiting Universitaire Ziekenhuizen KU Leuven · Antwerp and 5 other locations · NCT07727694

• BCB-276 CAR T therapy for DIPG in children and young adults

  This study tests BCB-276, a patient's own CAR T cells against DIPG, after standard radiation, to see if it is safe and can help extend survival.

  Recruiting at 3 sites Phase 2 BrainChild Bio, Inc · Los Angeles, California and 5 other locations · NCT07680439

• CAYA cancer patients in LMICs: a forward-looking observation of care and outcomes

  This study follows children, teens, and young adults with cancer in low- and middle-income countries to see how routine care affects treatment, access, and outcomes over time.

  Recruiting Resonance, Inc. · Yerevan and 5 other locations · NCT07632014

• Virtual reality headsets to reduce anxiety and fear during intrathecal chemotherapy in children

  This project will try virtual reality headsets with children aged 4–10 who are receiving intrathecal chemotherapy to see if they reduce anxiety, fear, and changes in vital signs.

  Recruiting TC Erciyes University · Kayseri · NCT07537062

• Laser thermal therapy for young people with low-grade glioma

  This research will test whether laser interstitial thermal therapy (LITT) can stop or slow recurrent or progressive low-grade gliomas in children, adolescents, and young adults.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07506239

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.